Abstract:PGAP2 gene has been known to be the cause of "hyperphosphatasia, mental retardation syndrome-3" (HPMRS3). To date, 14 pathogenic variants in PGAP2 have been identified as the cause of this syndrome in 24 patients described in single-case reports or small clinical series with pan-ethnic distribution. We aim to present a pediatric PGAP2 -mutated case, intending to further expand the clinical phenotype of the syndrome and to report our experience on a therapeutic approach to drug-resistant epilepsy. We present the clinical, neuroradiological, and genetic characterization of a Caucasian pediatric subject with biallelic pathogenic variants in the PGAP2 gene revealed by next generation sequencing analysis. We identified a subject who presented with global developmental delay and visual impairment. Brain magnetic resonance imaging showed mild hypoplasia of the inferior cerebellar vermis and corpus callosum and mild white matter reduction. Laboratory investigations detected an increase in alkaline phosphatase. At the age of 13 months, he began to present epileptic focal seizures with impaired awareness, which did not respond to various antiseizure medications. Electroencephalogram (EEG) showed progressive background activity disorganization and multifocal epileptic abnormalities. Treatment with high-dose pyridoxine showed partial benefit, but the persistence of seizures and the lack of EEG amelioration prompted us to introduce ketogenic diet treatment. Our case provides a further phenotypical expansion of HPMRS3 to include developmental and epileptic encephalopathy. Due to the limited number of patients reported so far, the full delineation of the clinical spectrum of HPMRS3 and indications for precision medicine would benefit from the description of new cases and their follow-up evaluations. Ethics committee approval is not required because genetic analyses are only for clinical diagnosis. Consent from patients and parents was obtained to publish detailed medical histories of patients. A.S., M.T., C.V., and S.O. were responsible for the conception and design of the paper; A.S., M.T., C.V., and S.O. wrote the original draft of the paper; S.G., M.P., E.R., G.P., and V.D.G. analyzed data. All authors contributed to the writing of the final manuscript. V.D.G. received research fundings and speaker fees from Eisai srl, GW Pharmaceuticals, Neu-raxpharm, Nutricia, Kanso, and Nestlè. V.D.G., S.G., A.P., M.P., E.R., C.V., and S.O. received financial support from the Italian Ministry of Health (RC 2022-2024) for the IRCCS Mondino Foundation in Pavia, Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. * Drs Saracino and Totaro equally contributed to this investigation (co-first authors) Received: 29 September 2023 Accepted: 02 January 2024 Article published online: 16 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Defining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases

Unique clinical presentations and follow-up outcomes from experience with congenital disorders of glycosylation: PMM2-PGM1-DPAGT1-MPI-POMT2-B3GALNT2-DPM1-SRD5A3-CDG

Cerebral visual impairment and intellectual disability caused by PGAP1 variants

Macrocephaly and Digital Anomalies Expand the Phenotypic Spectrum of PGAP2 Variants in Hyperphosphatasia with Impaired Intellectual Development Syndrome 3 (HPMRS3)

Congenital Disorders of Glycosylation from a Neurological Perspective

ALG9-CDG: New Clinical Case and Review of the Literature

PIGO-CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations

Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III

PGAP2-Related Hyperphosphatasia-Mental Retardation Syndrome: Report of a Novel Patient, Toward a Broadening of Phenotypic Spectrum and Therapeutic Perspectives

Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition

Clinical and Molecular Genetic Characterization of Two Patients with Mutations in the Phosphoglucomutase 1 (PGM1) Gene

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Congenital disorder of glycosylation type 1a:a case report

Congenital diaphragmatic hernia in siblings with PIGA-related congenital disorder of glycosylation

Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis

Missense variant in PIGM associated with severe cystic encephalomalacia and portal vein thrombosis: Phenotypic and genotypic expansion of the glycosylphosphatidylinositol biosynthesis defect-1 (GPIBD1)

Significantly different clinical phenotypes associated with mutations in synthesis and transamidase+remodeling glycosylphosphatidylinositol (GPI)-anchor biosynthesis genes

Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient

The clinical and genetic spectrum of inherited glycosylphosphatidylinositol deficiency disorders

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

Congenital Disorder of Glycosylation Type Ⅰg: a Case Report and Literature Review